Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02-AG) in Italy

AIDS Research and Human Retroviruses

Volumn 28, Issue 10, 2012, Pages 1285-1293

  Santoro, Maria Mercedes ^a   Alteri, Claudia ^a   Ronga, Luigi ^a,b   Flandre, Philippe ^c   Fabeni, Lavinia ^d   Mercurio, Fabio ^a   D'Arrigo, Roberta ^d   Gori, Caterina ^d   Palamara, Guido ^e   Bertoli, Ada ^f   Forbici, Federica ^d   Salpini, Romina ^a   Boumis, Evangelo ^d   Tozzi, Valerio ^d   Visco Comandini, Ubaldo ^d   Zaccarelli, Mauro ^d   Van Houtte, Margriet ^g   Pattery, Theresa ^g   Narciso, Pasquale ^d   Antinori, Andrea ^d   Ceccherini Silberstein, Francesca ^a   Perno, Carlo Federico ^a,d,f   more..

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^f TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^g Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE C; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE CRF02 AG; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE F; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE NON B; ITALY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV SEROPOSITIVITY; HIV-1; HUMANS; ITALY; MALE; MIDDLE AGED; MUTATION, MISSENSE; PHYLOGENY; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 84863546406     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0142     Document Type: Article

References (51)

1. Buonaguro L, Tornesello ML, and Buonaguro FM: Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: Pathogenetic and therapeutic implications. J Virol 2007;81:10209-10219.
2. Holgúin A, Ramirez de Arellano E, Rivas P, and Soriano V: Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev 2006;8:98-107.
3. Peeters M, Aghokeng AF, and Delaporte E: Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays. Clin Microbiol Infect 2010;16:1525-1531.
4. Hemelaar J, Gouws E, Ghys PD, and Osmanov S, and the WHO-UNAIDS Network for HIV Isolation and Characterisation: Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011;13:679-689.
5. Kantor R, Shafer RW, and Katzenstein D, and the HIV-1 Non-subtype B Workgroup: The HIV-1 Non-subtype B Workgroup: An international collaboration for the collection and analysis of HIV-1 non-subtype B data. MedGenMed 2005;23:71.
6. Barin F, Courouce AM, Pillonel J, et al.: Increasing diversity of HIV-1M serotypes in French blood donors over a 10-year period (1985-1995). Retrovirus Study Group of the French Society of Blood Transfusion. AIDS 1997;11:1503-1508.
7. Weidle PJ, Ganea CE, Irwin KL, et al.: Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: A sentinel site for monitoring HIV genetic diversity in the United States. J Infect Dis 2000;181:470-475.
8. Yerly S, Vora S, Rizzardi P et al.: Acute HIV infection: Impact on the spread of HIV and transmission of drug resistance. AIDS 2001;15:2287-2292.
9. Lai A, Riva C, Marconi A, et al.: Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades. HIV Med 2010;11:593-602.
10. Alteri C, Svicher V, Gori C, et al.: Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients näive to the antiretroviral drugs. BMC Infect Dis 2009;9:111.
11. Bracciale L, Colafigli M, Zazzi M, et al.: Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: Evolution over 12 years and predictors. J Anti-microb Chemother 2009;64:607-615.
12. Riva C, Lai A, Caramma I, et al.: Transmitted HIV type 1 drug resistance and non-B subtypes prevalence among ser-oconverters and newly diagnosed patients from 1992 to 2005 in Italy. AIDS Res Hum Retroviruses 2010;26:41-49.
13. Giuliani M, Montieri S, Palamara G, et al.: Non-B HIV-1 subtypes among men who have sex with men in Rome, Italy. AIDS Res Human Retroviruses 2009;25:1-8.
14. Monno L, Brindicci G, Lo Caputo S, et al.: HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern Italy. J Med Virol 2005;75:483-490.
15. Tramuto F, Bonura F, Perna AM, et al.: Group for HIV-1 Antiretroviral Studies in Sicily. Genetic diversity of HIV-1 non-B strains in Sicily: Evidence of intersubtype recombi-nants by sequence analysis of gag, pol, and env genes. AIDS Res Hum Retroviruses 2007;23:1131-1138.
16. Torti C, Lapadula G, Izzo I, et al.: Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: Public health implications. Epidemiol Infect 2010;29:1-10.
17. Geretti AM, Harrison L, Green H, et al.: Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009;48: 1296-1305.
18. Martínez-Cajas JL, Pant-Pai N, Klein MB, and Wainberg MA: Role of genetic diversity among HIV-1 non-B subtypes in drug resistance: A systematic review of virologic and biochemical evidence. AIDS Rev 2008;10:212-223.
19. Marcelin AG, Masquelier B, Descamps D, et al.: Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2008; 52:3237-3243.
20. Doualla-Bell F, Avalos A, Brenner B, et al.: High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 2006;50:4182-4185.
21. Brenner BG, Oliveira M, Doualla-Bell F, et al.: HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006;20:F9-F13.
22. Miller MD, Margot N, McColl D, and Cheng AK.: K65R development among subtype C HIV-1 patients in tenofovir DF clinical trials. AIDS 2007;21:265-266.
23. Coutsinos D, Invernizzi CF, Xu H, et al.: Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol 2009;83:2029-2033.
24. Ceccherini-Silberstein F, Erba F, Gago F, et al.: Identification of the minimal conserved structure of HIV-1 protease in the presence or absence of drug pressure. AIDS 2004;18:11-19.
25. Thompson JD, Higgins DG, and Gibson TJ: Clustal W: Improving sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res 1994;22:4673-4680.
26. Hall TA: Bioedit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98 NT. Nucl Acids Symp Ser 1999;41:95-98.
27. De Oliveira T, Deforche K, Cassol S, et al.: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005;21:3797-3800.
28. Swafford KL: PAUP 4.0: Phylogenetic analysis with parsimony (and other methods), version 4,0b2a. Sinauer Associates Inc., Sunderland, MA, 1999.
29. Posada D and Crandall KA: MODEL TEST: Testing the model of DNA substitution. Bioinformatics 1998;14:817-818.
30. Johnson, VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010;17:156-163.
31. Stanford HIV drug resistance, last updated on Jun 10, 2008. http://hivdb.stanford.edu/.
32. García-Lerma JG, MacInnes H, Bennett D, et al.: A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol 2003;77:5685-5693.
33. Abecasis AB, Deforche K, Snoeck J, et al.: Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 2005;19:1799-1806.
34. McKeage K, Perry CM, and Keam SJ: Darunavir: A review of its use in the management of HIV infection in adults. Drugs 2009;69:477-503.
35. van de Vijver DA, Wensing AM, Angarano G, et al.: The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006;41:352-360.
36. De Mendoza C, Garrido C, Poveda E, et al.: Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain. AIDS Res Hum Retroviruses 2009;25:967-972
37. Munerato P, Sucupira MC, Oliveros MP, et al.: HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil. AIDS Res Hum Retroviruses 2010;26(3):265-273.
38. Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG, and Wainberg MA: Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis 2009;200:1202-1206.
39. Miller MD, Margot N, Lu B, et al.: Genotypic and phenotypic predictors of the magnitude of response to tenofovir dis-oproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004;189:837-846.
40. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, and Merigan TC: Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Che-mother 1997;41:757-762.
41. Brenner BG and Coutsinos D: The K65R mutation in HIV-1 reverse transcriptase: Genetic barriers, resistance profile and clinical implications. HIV Ther 2009;3:583-594.
42. Kleim JP, Rösner M, Winkler I, et al.: Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74/Val or Ile and Val-75/Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci USA 1996;93(1):34-38.
43. Koval CE, Dykes C, Wang J, and Demeter LM.: Relative replication fitness of efavirenz-resistant mutants of HIV-1: Correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103NRL100I by the nucleoside resistance mutation L74V. Virology 2006;353:184-192.
44. Flys TS, Chen S, Jones DC, et al.: Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr 2006;42:610-613.
45. Deshpande A, Jauvin V, Magnin N, et al.: Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: Resistance to AR. AIDS Res Hum Ret-roviruses 2007;23:335-340.
46. Grossman Z, Istomin V, Averbuch D, et al.: Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 2004;18:909-915.
47. Hsu LY, Subramaniam R, Bacheler L, and Paton NI: Characterization of mutations in CRF01-AE virus isolates from antiretroviral treatment-naive and-experienced patients in Singapore. J Acquir Immune Defic Syndr 2005;38:5-13.
48. Sunpath H, France H, Tarin M, et al.: Prospective analysis of HIV-1 Drug Resistance After Virologic Failure on Anti-retroviral Therapy (ART): Initial Results from a Paediatric Cohort Study from KZN, South Africa. 15th Conference on Retrovirus and Opportunistic Infections, Boston, MA, 2008.
49. Gonzalez, LMF, Brindeiro, RM, Aguiar, RS, et al.: Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother 2004;48:3552-3555.
50. Calazans A, Brindeiro R, Brindeiro P, et al.: Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. J Infect Dis 2005;191:1961-1170.
51. Gonzalez A, Santos AF, Abecasis AB, et al.: Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates. J Antimicrobial Chemother 2008;61:1201-1204.